LIGAND PHARMACEUTICALS
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified,... and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.
LIGAND PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1987-09-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.ligand.com
Total Employee:
101+
Status:
Active
Contact:
858-550-7500
Total Funding:
875 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Universal Analytics Apache Microsoft Exchange Online
Similar Organizations
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Board_member
Board_member
2010-10-01
Current Employees Featured
John L. Higgins CEO @ Ligand Pharmaceuticals
CEO
Melanie Herman Chief Accounting Officer and Interim CFO @ Ligand Pharmaceuticals
Chief Accounting Officer and Interim CFO
2015-05-01
Brook Byers Founder @ Ligand Pharmaceuticals
Founder
Matthew Korenberg Executive Vice President, Finance & CFO @ Ligand Pharmaceuticals
Executive Vice President, Finance & CFO
2015-08-01
Matthew Foehr President & Chief Operating Officer @ Ligand Pharmaceuticals
President & Chief Operating Officer
Bob Chen Director, Systems Engineering and Site Head @ Ligand Pharmaceuticals
Director, Systems Engineering and Site Head
2020-01-01
David J. Mangelsdorf Team Member @ Ligand Pharmaceuticals
Team Member
John Kozarich Chairman of the Board @ Ligand Pharmaceuticals
Chairman of the Board
2003-03-01
Christel Aperlo VP, Antibody Technologies @ Ligand Pharmaceuticals
VP, Antibody Technologies
2017-01-01
Bob Chen Sr. Director, Systems Engineering @ Ligand Pharmaceuticals
Sr. Director, Systems Engineering
2021-09-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-09-10 | xCella Biosciences | xCella Biosciences acquired by Ligand Pharmaceuticals | 7 M USD |
| 2020-09-10 | Taurus Biosciences | Taurus Biosciences acquired by Ligand Pharmaceuticals | 5 M USD |
| 2020-08-10 | Pfenex | Pfenex acquired by Ligand Pharmaceuticals | 438 M USD |
| 2020-02-11 | Icagen - Core Assets, Partnered Programs And ION Channel Technologies | Icagen - Core Assets, Partnered Programs And ION Channel Technologies acquired by Ligand Pharmaceuticals | 15 M USD |
| 2019-07-23 | Ab Initio Biotherapeutics | Ab Initio Biotherapeutics acquired by Ligand Pharmaceuticals | 12 M USD |
| 2018-08-09 | Vernalis | Vernalis acquired by Ligand Pharmaceuticals | 43 M USD |
| 2017-10-04 | Crystal Bioscience | Crystal Bioscience acquired by Ligand Pharmaceuticals | 35.5 M USD |
| 2015-12-18 | OMT | OMT acquired by Ligand Pharmaceuticals | 178 M USD |
| 2015-05-11 | Selexis | Selexis acquired by Ligand Pharmaceuticals | 4 M USD |
| 2011-01-27 | CyDex Pharmaceuticals | CyDex Pharmaceuticals acquired by Ligand Pharmaceuticals | N/A |
Investors List
Venrock
Venrock investment in Seed Round - Ligand Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2020-05-28 | Palvella Therapeutics | Ligand Pharmaceuticals investment in Series C - Palvella Therapeutics | 45 M USD |
| 2019-02-05 | Dianomi Therapeutics | Ligand Pharmaceuticals investment in Corporate Round - Dianomi Therapeutics | 3 M USD |
| 2018-12-18 | Palvella Therapeutics | Ligand Pharmaceuticals investment in Corporate Round - Palvella Therapeutics | 10 M USD |
| 2014-05-26 | Viking Therapeutics | Ligand Pharmaceuticals investment in Debt Financing - Viking Therapeutics | 2.5 M USD |
Official Site Inspections
http://www.ligand.com Semrush global rank: 2.67 M Semrush visits lastest month: 6.27 K
- Host name: 104.21.89.4
- IP address: 104.21.89.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Ligand Pharmaceuticals"
Ligand Pharmaceuticals - Biopharma's …
Ligand invests in the clinical development and commercialization of high-value medicines. We manage one of the largest and most diverse portfolios of biopharmaceutical royalties in the …See details»
About Us - Ligand Pharmaceuticals
Investors working at the intersection of development and commercialization. Ligand is a biopharmaceutical company that invests in the groundbreaking medicines of today and …See details»
Home | Innovation + Impact
LIGAND INNOVATION GLOBAL. 400-5025 Orbitor Dr Bld 4, Mississauga ON . L4W 4Y5, Canada. ceo@ligandcorp.com . Tel: 647-780-6413 ...See details»
Ligand Pharmaceuticals - Wikipedia
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company located in San Diego, California. [4] Founded in 1987 as Progenix Inc., the company went public in 1992.Initially …See details»
Ligand Pharmaceuticals: Employee Directory | ZoomInfo.com
Founded in 1987, Ligand Pharmaceuticals biopharmaceutical company focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop …See details»
Ligand Pharmaceuticals Incorporated - VentureRadar
Ligand’s Protein Expression Technology® is a robust, validated, cost-effective and scalable approach to recombinant protein production, and is especially well-suited for complex, large …See details»
Ligand Pharmaceuticals Incorporated - Cruelty Free Investing
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. …See details»
Ligand Pharmaceuticals Incorporated - Ligand Spins Out and …
Sep 18, 2023 Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biology …See details»
News & Events - Press Releases - Ligand Pharmaceuticals
Feb 6, 2025 At Ligand Pharmaceuticals Incorporated, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the …See details»
Ligand Pharmaceuticals Incorporated - GenScript Biotech and …
Jun 2, 2021 GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement Download as PDF June 02, 2021 GenScript Biotech Corporation (HKG: …See details»
Ligandal - Crunchbase Company Profile & Funding
Ligandal's mission is to create precision delivery platform to cure and treat disease. We are driving the discovery and delivery of a broad array of gene therapies, genetic materials, and gene-specific payloads with unprecedented …See details»
Careers - Ligand Pharmaceuticals
Careers Ligand is a dynamic, fast-paced organization. We look for innovative, efficient, versatile, self-starters who take great pride in their work and want to contribute to something significant. …See details»
Ligand Partner Prism Pharmaceuticals to be Acquired by Baxter
Apr 20, 2011 Baxter to Commercialize Nexterone® SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced that its partner Prism …See details»
Royalty Portfolio - Ligand Pharmaceuticals
Attractive programs with high clinical value. Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 90 partnered …See details»
Earnings call transcript: Ligand Pharmaceuticals Q4 2024 earnings …
Feb 27, 2025 Ligand Pharmaceuticals (NASDAQ: LGND) reported strong financial results for Q4 2024, surpassing analyst expectations with an EPS of $1.27 compared to the forecasted …See details»
Ligand Pharmaceuticals Incorporated - Ligand to Report Fourth …
Feb 13, 2025 Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report fourth quarter and full year 2024 financial results before the opening of the U.S. financial …See details»
Ligand Pharmaceuticals Incorporated - OmniAb Business …
Oct 24, 2022 OmniAb Business Combination Approved by APAC Shareholders Download as PDF October 24, 2022 APAC Shareholder Approval Obtained, Closing Scheduled for …See details»
Beyond vessels: unraveling the impact of VEGFs on neuronal …
Mar 6, 2025 Ligand binding induces the dimerization of VEGFRs to homo- or heterodimers, followed by activation of the receptors ... including neurite outgrowth, growth cone …See details»
Batch correcting single-cell spatial transcriptomics count data with ...
Feb 25, 2025 By correcting for batch effects, Crescendo enhances spatial transcriptomics analyses to detect gene colocalization and ligand-receptor interactions and enables cross …See details»
Histological signatures map anti-fibrotic factors in mouse and …
3 days ago Fibrosis, the replacement of healthy tissue with collagen-rich matrix, can occur following injury in almost every organ1,2. Mouse lungs follow a stereotyped sequence of …See details»